Evidence map›Paper›PMID 41996129›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2026

AR and Beyond: ctDNA Maps Resistance Evolution in mCRPC.

Pradeep S Chauhan, Russell K Pachynski, Christopher A Maher, Aadel A Chaudhuri

Abstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Pradeep S ChauhanDepartment of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0003-4304-011X
Russell K PachynskiDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri.ORCID 0000-0002-8966-7631
Christopher A MaherDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri.ORCID 0000-0002-9035-603X
Aadel A ChaudhuriDepartment of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0003-3115-3061

Funding

Novel ctDNA biomarker for androgen therapy in metastatic prostate cancerR01CA286127 · NCI · WASHINGTON UNIVERSITY · PI Aadel Chaudhuri, Christopher A Maher · 2024 to 2026
$1.8M
NCI NIH HHS R01 CA286127
6 · The paper itself

Abstract

Longitudinal plasma cell-free DNA profiling from the phase 3 Alliance A031201 trial revealed divergent resistance trajectories in metastatic castration-resistant prostate cancer. Rapid progressors harbored non-androgen receptor (AR) alterations suggesting intrinsic resistance, whereas delayed progressors showed progressive AR amplifications, structural rearrangements, and extrachromosomal DNA-associated evolution. These findings support biomarker-guided strategies targeting AR-dependent and AR-independent disease states. See related article by Valentín López et al., p. 2413.

Indexed as

Biomarkers, TumorCirculating Tumor DNADrug Resistance, NeoplasmProstatic Neoplasms, Castration-ResistantReceptors, AndrogenHumansMaleAR protein, humanBiomarkers, TumorCirculating Tumor DNAReceptors, Androgen

Identifiers

PMID41996129
PMCPMC13252709

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.